Key facts
- Angiocrine Bioscience’s last known valuation is $25.1M (Sep 2025).
- It has raised $88.8M across 2 recorded rounds; the latest was Seed Round ($2.1M) in Aug 2025.
- Notable investors include Good Growth Capital, Dubin & Co., Axil Capital Partners, California Institute for Regenerative Medicine, Cobro Ventures — 7 tracked in total.
- Angiocrine Bioscience has filed 2 Form Ds with the SEC since 2021, most recently Sep 2025 ($2.1M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Angiocrine Bioscience
Funding rounds
2 roundsAbout Angiocrine Bioscience
Developer of a curative cellular therapies platform designed to treat indications in regenerative medicine and hematopoietic stem cell gene therapy. The company's platform comprises cultured endothelial cells that are genetically modified via insertion of the adenovirus gene, enabling physicians to improvise their treatment and therapeutic procedures.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2012
- Employees
- 15
- Website
- angiocrinebioscience.com/
- Ownership
- Privately Held (backing)
Angiocrine Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Angiocrine Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Angiocrine Bioscience in its N-PORT filings yet. We sweep new filings monthly.